MyImmune Corporation
PrivateLast Round
Accelerator
Jul 1, 2026
Momentum
Top 10%
of companies Caplight tracks
Company Overview
MyImmune Corporation operates in Healthcare & Life Sciences and is based in Wilmington, Delaware. Its latest recorded funding round was an Accelerator round in July 2026.
MyImmune Corporation is a biotechnology company that utilizes an artificial intelligence platform to analyze adaptive immune receptor data for disease diagnosis and therapeutic development.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials, Medical AI
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
MyImmune Corporation Comparables
Compare MyImmune Corporation with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Onyx Bio | 86% | |
| Etcembly | 77% | |
| iRepertoire, Inc. | 76% |
For institutional investors. Book with your work email.
MyImmune Corporation Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Accelerator | Jul 1, 2026 | ||||
| Pre Seed | Oct 23, 2024 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
MyImmune Corporation Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| MassChallenge Israel | Accelerator |
| OUVC | Pre Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 184% MoM.
- Jul 1, 2026
Received funding from MassChallenge Israel.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingSep 16, 2026
On Sep 16th '26 in Japan, MyImmune Corporation is developing "AbSapien," a platform that uses AI to identify promising human candidates for antibody therapeutics from existing antibodies and other inputs, with the aim of reducing antibody discovery time.
For institutional investors. Book with your work email.
MyImmune Corporation Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about MyImmune Corporation's valuation, stock price, and market status.
Is MyImmune Corporation a public or private company?
MyImmune Corporation is a private company.
What is the current stock price of MyImmune Corporation?
MyImmune Corporation is a private company, so its shares have no public market price. Caplight tracks MyImmune Corporation's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is MyImmune Corporation worth (valuation)?
Valuation information for MyImmune Corporation is not publicly available.
Can I buy MyImmune Corporation stock?
MyImmune Corporation shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was MyImmune Corporation's last funding round?
MyImmune Corporation's most recent funding round was Accelerator on July 1, 2026.
Who are the main investors in MyImmune Corporation?
Key investors in MyImmune Corporation include OUVC.
Will MyImmune Corporation IPO soon?
No public IPO plans have been announced for MyImmune Corporation.
How can I track MyImmune Corporation secondary market activity?
Caplight tracks bids, offers, and trades in MyImmune Corporation's shares on secondary markets.